About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Japan Tissue Engineering Co., Ltd.(7774) Summary

7774
TSE Growth
Japan Tissue Engineering Co., Ltd.
448
JPY
-2
(-0.44%)
Apr 16, 3:30 pm JST
3.14
USD
Apr 16, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
3.18
Yield
ー%
Margin Trading Ratio
51.80
Stock Price
Apr 16, 2025
Opening Apr 16, 9:00 am
451 JPY 3.15 USD
Previous Close Apr 15
450 JPY 3.14 USD
High Apr 16, 1:37 pm
476 JPY 3.33 USD
Low Apr 16, 1:44 pm
438 JPY 3.07 USD
Volume
124,900
Trading Value
0.06B JPY 0.40M USD
VWAP
455.48 JPY 3.2 USD
Minimum Trading Value
44,800 JPY 314 USD
Market Cap
0.02T JPY 0.13B USD
Number of Trades
204
Liquidity & Number of Trades
As of Apr 16, 2025
Liquidity
Mid
1-Year Average
125
1-Year High Jun 26, 2024
1,160
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 11, 2025 10,500 371,900 35.42
Apr 4, 2025 10,900 408,100 37.44
Mar 28, 2025 10,700 438,200 40.95
Mar 21, 2025 10,400 454,600 43.71
Mar 14, 2025 9,000 449,400 49.93
Company Profile
Japan Tissue Engineering Co., Ltd. is a regenerative medicine venture. The company develops autologous cultured epidermis and cartilage, among other products. It became a subsidiary of Teijin through a tender offer.
Sector
Precision Instruments
Japan Tissue Engineering Co., Ltd. focuses on the development, manufacturing, and sales of regenerative medicine products, as well as contracted regenerative medicine services for development and manufacturing, and research and development support. The company has five products: JACE (autologous cultured epidermis), JACC (autologous cultured cartilage), NEPIC (autologous cultured corneal epithelium), OCULAR (autologous cultured oral mucosal epithelium), and JASMINE (autologous cultured epidermis containing melanocytes). In its contracted regenerative medicine business, the company provides CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) services. The research and development support business offers the LabCyte series of human cultured tissues. As new pipelines, the company is working on the development of allogeneic cultured epidermis and CAR-T cell therapies. Japan Tissue Engineering Co., Ltd. is a member of the Teijin Group.